SCHEMBL8283871

SCHEMBL8283871

CCOC(=O)c1ccc2c(c1)nc(N)n2Cc1cccc2c1ncn2C

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ MAPT P10636 4/20 0.45
▸ NPSR1 Q6W5P4 1/20 0.45
▸ PTGER4 P35408 5/20 0.45
▸ NLRP3 Q96P20 1/20 0.44
▸ SIRT2 Q8IXJ6 6/20 0.44
▸ SIRT1 Q96EB6 4/20 0.44
▸ HTT P42858 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ RECQL P46063 1/20 0.42
▸ PDE2A O00408 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ HPGD P15428 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12226879 0.93 PDE2A (0.41) NPC1MEN1KMT2ARAB9AMAPT
SCHEMBL8284619 0.85 NPC1 (0.54) NPC1MEN1KMT2ARAB9AMAPT
SCHEMBL13773349 0.80 CDK1 (0.43) MEN1KMT2AMAPTPTGER4HTT
SCHEMBL8283872 0.79 TNF (0.41) KMT2AHTTALDH1A1POLB
SCHEMBL8285693 0.79 TNF (0.40) KMT2APTGER4HTTALDH1A1POLB
SCHEMBL8284609 0.77 NPC1 (0.45) NPC1MEN1KMT2ARAB9AMAPT
SCHEMBL22382307 0.77 KMT2A (0.63) NPC1MEN1KMT2ARAB9AMAPT
SCHEMBL12226891 0.76 NPC1 (0.49) NPC1MEN1KMT2ARAB9AMAPT
SCHEMBL8284622 0.75 SIRT2 (0.50) NPC1MEN1KMT2ARAB9AMAPT
SCHEMBL22382310 0.75 PTGER4 (0.63) NPC1MEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 — — US disclosed
US-8044073-B2 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication TIBOTEC PHARMACEUTICALS (IE) 2011-10-25 — — US disclosed
EP-1697343-B1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARM LTD (IE) 2009-07-01 — — EP disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 — — US disclosed
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication JANSSEN SCIENCES IRELAND UC (IE) 2007-05-03 — — US disclosed
WO-2005058869-A1 AMINOBENZIMIDAZOLES AND BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099924-A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-2, H1-4 NPC1 3348/4885MEN1 4025/4885KMT2A 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback